#PAGE_PARAMS# #ADS_HEAD_SCRIPTS# #MICRODATA#

Fructose-1,6-bisphosphate prevents pulmonary fibrosis by regulating extracellular matrix deposition and inducing phenotype reversal of lung myofibroblasts


Autoři: Henrique Bregolin Dias aff001;  Jarbas Rodrigues de Oliveira aff001;  Márcio Vinícius Fagundes Donadio aff001;  Shioko Kimura aff002
Působiště autorů: Laboratory of Cellular Biophysics and Inflammation, PUCRS, Porto Alegre, RS, Brazil aff001;  Laboratory of Metabolism, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, United States of America aff002
Vyšlo v časopise: PLoS ONE 14(9)
Kategorie: Research Article
doi: https://doi.org/10.1371/journal.pone.0222202

Souhrn

Pulmonary fibrosis (PF) is the result of chronic injury where fibroblasts become activated and secrete large amounts of extracellular matrix (ECM), leading to impaired fibroblasts degradation followed by stiffness and loss of lung function. Fructose-1,6-bisphosphate (FBP), an intermediate of glycolytic pathway, decreases PF development, but the underlying mechanism is unknown. To address this issue, PF was induced in vivo using a mouse model, and pulmonary fibroblasts were isolated from healthy and fibrotic animals. In PF model mice, lung function was improved by FBP as revealed by reduced collagen deposition and downregulation of ECM gene expression such as collagens and fibronectin. Fibrotic lung fibroblasts (FLF) treated with FBP for 3 days in vitro showed decreased proliferation, contraction, and migration, which are characteristic of myofibroblast to fibroblast phenotype reversal. ECM-related genes and proteins such as collagens, fibronectin and α-smooth muscle actin, were also downregulated in FBP-treated FLF. Moreover, matrix metalloproteinase (MMP) 1, responsible for ECM degradation, was produced only in fibroblasts obtained from healthy lungs (HLF) and FBP did not alter its expression. On the other hand, tissue inhibitor of metalloproteinase (TIMP)-1, a MMP1 inhibitor, and MMP2, related to fibroblast tissue-invasion, were predominantly produced by FLF and FBP was able to downregulate its expression. These results demonstrate that FBP may prevent bleomycin-induced PF development through reduced expression of collagen and other ECM components mediated by a reduced TIMP-1 and MMP2 expression.

Klíčová slova:

Biology and life sciences – Cell biology – Cellular types – Animal cells – Connective tissue cells – Fibroblasts – Anatomy – Biological tissue – Connective tissue – Biochemistry – Proteins – Collagens – Developmental biology – Organism development – Organogenesis – Lung development – Fibrosis – Pulmonary fibrosis – Genetics – Gene expression – Medicine and health sciences – Pulmonology – Pulmonary function – Diagnostic medicine – Diagnostic radiology – Pulmonary imaging – Radiology and imaging – Research and analysis methods – Imaging techniques


Zdroje

1. Raghu G, Collard HR, Egan JJ, Martinez FJ, Behr J, Brown KK, et al. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med. 2011;183(6):788–824. doi: 10.1164/rccm.2009-040GL 21471066

2. Provencher DM, Jauregui AR. Recommendations for evaluating and managing idiopathic pulmonary fibrosis. JAAPA. 2018;31(9):21–6. doi: 10.1097/01.JAA.0000544299.00459.a4 30095512

3. Tomos IP, Tzouvelekis A, Aidinis V, Manali ED, Bouros E, Bouros D, et al. Extracellular matrix remodeling in idiopathic pulmonary fibrosis. It is the 'bed' that counts and not 'the sleepers'. Expert Rev Respir Med. 2017;11(4):299–309. doi: 10.1080/17476348.2017.1300533 28274188

4. Murtha LA, Schuliga MJ, Mabotuwana NS, Hardy SA, Waters DW, Burgess JK, et al. The processes and mechanisms of cardiac and pulmonary fibrosis. Front Physiol. 2017;8:777. doi: 10.3389/fphys.2017.00777 29075197

5. Selman M, Ruiz V, Cabrera S, Segura L, Ramirez R, Barrios R, et al. TIMP-1, -2, -3, and -4 in idiopathic pulmonary fibrosis. A prevailing nondegradative lung microenvironment? Am J Physiol Lung Cell Mol Physiol. 2000;279(3):L562–74. doi: 10.1152/ajplung.2000.279.3.L562 10956632

6. Misharin AV, Budinger GRS. Targeting the myofibroblast in pulmonary fibrosis. Am J Respir Crit Care Med. 2018;198(7):834–5. doi: 10.1164/rccm.201806-1037ED 29966099

7. Hinz B, Phan SH, Thannickal VJ, Galli A, Bochaton-Piallat ML, Gabbiani G. The myofibroblast: one function, multiple origins. Am J Pathol. 2007;170(6):1807–16. doi: 10.2353/ajpath.2007.070112 17525249

8. Catarina AV, Luft C, Greggio S, Venturin GT, Ferreira F, Marques EP, et al. Fructose-1,6-bisphosphate preserves glucose metabolism integrity and reduces reactive oxygen species in the brain during experimental sepsis. Brain Res. 2018;1698:54–61 doi: 10.1016/j.brainres.2018.06.024 29932894

9. Santos RC, Moresco RN, Pena Rico MA, Susperregui AR, Rosa JL, Bartrons R, et al. Fructose-1,6-bisphosphate protects against Zymosan-induced acute lung injury in mice. Inflammation. 2012;35(3):1198–203. doi: 10.1007/s10753-012-9429-6 22327861

10. Krause GC, Lima KG, Haute GV, Schuster AD, Dias HB, Mesquita FC, et al. Fructose-1,6-bisphosphate decreases IL-8 levels and increases the activity of pro-apoptotic proteins in HepG2 cells. Biomed Pharmacother. 2017;89:358–65. doi: 10.1016/j.biopha.2017.01.178 28242545

11. Li Y, Wei W, Shen HW, Hu WQ. The study of inducing apoptosis effect of fructose 1,6-bisphosphate on the papillary thyroid carcinoma cell and its related mechanism. Tumour Biol. 2014;35(5):4539–44. doi: 10.1007/s13277-013-1597-y 24414485

12. Lu YX, Yu XC, Zhu MY. Antitumor effect of fructose 1,6-bisphosphate and its mechanism in hepatocellular carcinoma cells. Tumour Biol. 2014;35(2):1679–85. doi: 10.1007/s13277-013-1231-z 24081674

13. Alva N, Alva R, Carbonell T. Fructose 1,6-Bisphosphate: A summary of its cytoprotective mechanism. Curr Med Chem. 2016;23(39):4396–417. doi: 10.2174/0929867323666161014144250 27758716

14. de Mesquita FC, Bitencourt S, Caberlon E, da Silva GV, Basso BS, Schmid J, et al. Fructose-1,6-bisphosphate induces phenotypic reversion of activated hepatic stellate cell. Eur J Pharmacol. 2013;720(1–3):320–5. doi: 10.1016/j.ejphar.2013.09.067 24144957

15. Dias HB, Krause GC, Squizani ED, Lima KG, Schuster AD, Pedrazza L, et al. Fructose-1,6-bisphosphate reverts iron-induced phenotype of hepatic stellate cells by chelating ferrous ions. Biometals. 2017;30(4):549–58. doi: 10.1007/s10534-017-0025-y 28639108

16. Jost RT, Dias HB, Krause GC, de Souza RG, de Souza TR, Nunez NK, et al. Fructose-1,6-bisphosphate prevents bleomycin-induced pulmonary fibrosis in mice and inhibits the proliferation of lung fibroblasts. Inflammation. 2018;41(5):1987–2001. doi: 10.1007/s10753-018-0842-3 29995294

17. Cai Y, Kimura S. Noninvasive intratracheal intubation to study the pathology and physiology of mouse lung. J Vis Exp. 2013;(81):e50601. doi: 10.3791/50601 24300823

18. Santos RC, Moresco RN, Pena Rico MA, Susperregui AR, Rosa JL, Bartrons R, et al. Fructose-1,6-bisphosphate reduces the mortality in Candida albicans bloodstream infection and prevents the septic-induced platelet decrease. Inflammation. 2012;35(4):1256–61. E doi: 10.1007/s10753-012-9436-7 22367598

19. Hubner RH, Gitter W, El Mokhtari NE, Mathiak M, Both M, Bolte H, et al. Standardized quantification of pulmonary fibrosis in histological samples. Biotechniques. 2008;44(4):507–11, 14–7. doi: 10.2144/000112729 18476815

20. Shoulders MD, Raines RT. Collagen structure and stability. Annu Rev Biochem. 2009;78:929–58. doi: 10.1146/annurev.biochem.77.032207.120833 19344236

21. Moore BB, Hogaboam CM. Murine models of pulmonary fibrosis. Am J Physiol Lung Cell Mol Physiol. 2008;294(2):L152–60. doi: 10.1152/ajplung.00313.2007 17993587

22. Phan SH, Kunkel SL. Lung cytokine production in bleomycin-induced pulmonary fibrosis. Exp Lung Res. 1992;18(1):29–43. doi: 10.3109/01902149209020649 1374023

23. Simon MM, Greenaway S, White JK, Fuchs H, Gailus-Durner V, Wells S, et al. A comparative phenotypic and genomic analysis of C57BL/6J and C57BL/6N mouse strains. Genome Biol. 2013;14(7):R82. doi: 10.1186/gb-2013-14-7-r82 23902802

24. Navarro A, Rezaiekhaligh M, Keightley JA, Mabry SM, Perez RE, Ekekezie, II. Higher TRIP-1 level explains diminished collagen contraction ability of fetal versus adult fibroblasts. Am J Physiol Lung Cell Mol Physiol. 2009;296(6):L928–35. doi: 10.1152/ajplung.00012.2009 19329541

25. Jonsson MKB, Hartman RJG, Ackers-Johnson M, Tan WLW, Lim B, van Veen TAB, et al. A transcriptomic and epigenomic comparison of fetal and adult human cardiac fibroblasts reveals novel key transcription factors in adult cardiac fibroblasts. JACC Basic Transl Sci. 2016;1(7):590–602. doi: 10.1016/j.jacbts.2016.07.007 30167544

26. Pratsinis H, Kletsas D, Stathakos D. Autocrine growth regulation in fetal and adult human fibroblasts. Biochem Biophys Res Commun. 1997;237(2):348–53. doi: 10.1006/bbrc.1997.7136 9268714

27. Sano W, Watanabe F, Tamai H, Furuya E, Mino M. Beneficial effect of fructose-1,6-bisphosphate on mitochondrial function during ischemia-reperfusion of rat liver. Gastroenterology. 1995;108(6):1785–92. doi: 10.1016/0016-5085(95)90141-8 7768384

28. Hardin CD, Roberts TM. Metabolism of exogenously applied fructose 1,6-bisphosphate in hypoxic vascular smooth muscle. Am J Physiol. 1994;267(6 Pt 2):H2325–32.

29. Ehringer WD, Su S, Chiangb B, Stillwell W, Chien S. Destabilizing effects of fructose-1,6-bisphosphate on membrane bilayers. Lipids. 2002;37(9):885–92. doi: 10.1007/s11745-002-0975-2 12458624

30. Hardin CD, Lazzarino G, Tavazzi B, Di Pierro D, Roberts TM, Giardina B, et al. Myocardial metabolism of exogenous FDP is consistent with transport by a dicarboxylate transporter. Am J Physiol Heart Circ Physiol. 2001;281(6):H2654–60. doi: 10.1152/ajpheart.2001.281.6.H2654 11709435

31. Hirokawa F, Nakai T, Yamaue H. Storage solution containing fructose-1,6-bisphosphate inhibits the excess activation of Kupffer cells in cold liver preservation. Transplantation. 2002;74(6):779–83. doi: 10.1097/00007890-200209270-00008 12364855

32. Moresco RN, Santos RC, Alves Filho JC, Cunha AA, Dos Reis C, Reichel CL, et al. Protective effect of fructose-1,6-bisphosphate in the cold storage solution for liver preservation in rat hepatic transplantation. Transplant Proc. 2004;36(5):1261–4. doi: 10.1016/j.transproceed.2004.05.040 15251307

33. Didlake R, Kirchner KA, Lewin J, Bower JD, Markov A. Protection from ischemic renal injury by fructose-1,6-diphosphate infusion in the rat. Circ Shock. 1985;16(2):205–12. 4053295

34. Kaakinen T, Heikkinen J, Dahlbacka S, Alaoja H, Laurila P, Kiviluoma K, et al. Fructose-1,6-bisphosphate supports cerebral energy metabolism in pigs after ischemic brain injury caused by experimental particle embolization. Heart Surg Forum. 2006;9(6):E828–35. doi: 10.1532/HSF98.20061079 16893758

35. Xu K, Stringer JL. Pharmacokinetics of fructose-1,6-diphosphate after intraperitoneal and oral administration to adult rats. Pharmacol Res. 2008;57(3):234–8. doi: 10.1016/j.phrs.2008.01.008 18325780

36. Li TT, Xie JZ, Wang L, Gao YY, Jiang XH. Rational application of fructose-1,6-diphosphate: From the perspective of pharmacokinetics. Acta Pharm. 2015;65(2):147–57. doi: 10.1515/acph-2015-0020 26011931

37. Chu SJ, Chang DM, Wang D, Chen YH, Hsu CW, Hsu K. Fructose-1,6-diphosphate attenuates acute lung injury induced by ischemia-reperfusion in rats. Crit Care Med. 2002;30(7):1605–9. doi: 10.1097/00003246-200207000-00034 12130986

38. Nava S, Rubini F. Lung and chest wall mechanics in ventilated patients with end stage idiopathic pulmonary fibrosis. Thorax. 1999;54(5):390–5. doi: 10.1136/thx.54.5.390 10212101

39. Kristensen JH, Karsdal MA, Genovese F, Johnson S, Svensson B, Jacobsen S, et al. The role of extracellular matrix quality in pulmonary fibrosis. Respiration. 2014;88(6):487–99. doi: 10.1159/000368163 25359084

40. Houghton AM. Matrix metalloproteinases in destructive lung disease. Matrix Biol. 2015;44–46:167–74. doi: 10.1016/j.matbio.2015.02.002 25686691

41. Vanoirbeek JA, Rinaldi M, De Vooght V, Haenen S, Bobic S, Gayan-Ramirez G, et al. Noninvasive and invasive pulmonary function in mouse models of obstructive and restrictive respiratory diseases. Am J Respir Cell Mol Biol. 2010;42(1):96–104. doi: 10.1165/rcmb.2008-0487OC 19346316

42. Barry-Hamilton V, Spangler R, Marshall D, McCauley S, Rodriguez HM, Oyasu M, et al. Allosteric inhibition of lysyl oxidase-like-2 impedes the development of a pathologic microenvironment. Nat Med. 2010;16(9):1009–17. doi: 10.1038/nm.2208 20818376

43. Oggionni T, Morbini P, Inghilleri S, Palladini G, Tozzi R, Vitulo P, et al. Time course of matrix metalloproteases and tissue inhibitors in bleomycin-induced pulmonary fibrosis. Eur J Histochem. 2006;50(4):317–25. 17213041

44. Bringardner BD, Baran CP, Eubank TD, Marsh CB. The role of inflammation in the pathogenesis of idiopathic pulmonary fibrosis. Antioxid Redox Signal. 2008;10(2):287–301. doi: 10.1089/ars.2007.1897 17961066

45. Domanska UM, Kruizinga RC, Nagengast WB, Timmer-Bosscha H, Huls G, de Vries EG, et al. A review on CXCR4/CXCL12 axis in oncology: no place to hide. Eur J Cancer. 2013;49(1):219–30. doi: 10.1016/j.ejca.2012.05.005 22683307

46. Lin CH, Shih CH, Tseng CC, Yu CC, Tsai YJ, Bien MY, et al. CXCL12 induces connective tissue growth factor expression in human lung fibroblasts through the Rac1/ERK, JNK, and AP-1 pathways. PLoS One. 2014;9(8):e104746. doi: 10.1371/journal.pone.0104746 25121739

47. Zhao X, Psarianos P, Ghoraie LS, Yip K, Goldstein D, Gilbert R, et al. Metabolic regulation of dermal fibroblasts contributes to skin extracellular matrix homeostasis and fibrosis. Nature Metabolism. 2019;1(1):147–57.

48. Choi H, Yang SH, Bae IH, Park JY, Kim HJ, Noh M, et al. Fructose 1, 6-diphosphate regulates desmosomal proteins and collagen fibres in human skin equivalents. Exp Dermatol. 2013;22(12):847–9. doi: 10.1111/exd.12279 24171778

49. Xie N, Tan Z, Banerjee S, Cui H, Ge J, Liu RM, et al. Glycolytic reprogramming in myofibroblast differentiation and lung fibrosis. Am J Respir Crit Care Med. 2015;192(12):1462–74. doi: 10.1164/rccm.201504-0780OC 26284610

50. Zhao YD, Yin L, Archer S, Lu C, Zhao G, Yao Y, et al. Metabolic heterogeneity of idiopathic pulmonary fibrosis: a metabolomic study. BMJ Open Respir Res. 2017;4(1):e000183. doi: 10.1136/bmjresp-2017-000183 28883924

51. Vander Heiden MG, Cantley LC, Thompson CB. Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science. 2009;324(5930):1029–33. doi: 10.1126/science.1160809 19460998

52. Veras FP, Peres RS, Saraiva AL, Pinto LG, Louzada-Junior P, Cunha TM, et al. Fructose 1,6-bisphosphate, a high-energy intermediate of glycolysis, attenuates experimental arthritis by activating anti-inflammatory adenosinergic pathway. Sci Rep. 2015;5:15171. doi: 10.1038/srep15171 26478088

53. Espanol MT, Litt L, Hasegawa K, Chang LH, Macdonald JM, Gregory G, et al. Fructose-1,6-bisphosphate preserves adenosine triphosphate but not intracellular pH during hypoxia in respiring neonatal rat brain slices. Anesthesiology. 1998;88(2):461–72. doi: 10.1097/00000542-199802000-00025 9477067

54. Underwood AH, Newsholme EA. Properties of phosphofructokinase from rat liver and their relation to the control of glycolysis and gluconeogenesis. Biochem J. 1965;95:868–75. doi: 10.1042/bj0950868 14342527

55. Phan SH. Biology of fibroblasts and myofibroblasts. Proc Am Thorac Soc. 2008;5(3):334–7. doi: 10.1513/pats.200708-146DR 18403329

56. Waters DW, Blokland KEC, Pathinayake PS, Burgess JK, Mutsaers SE, Prele CM, et al. Fibroblast senescence in the pathology of idiopathic pulmonary fibrosis. Am J Physiol Lung Cell Mol Physiol. 2018;315(2):L162–L72. doi: 10.1152/ajplung.00037.2018 29696986

57. da Silva EF, Krause GC, Lima KG, Haute GV, Pedrazza L, Mesquita FC, et al. Rapamycin and fructose-1,6-bisphosphate reduce the HEPG2 cell proliferation via increase of free radicals and apoptosis. Oncol Rep. 2016;36(5):2647–52. doi: 10.3892/or.2016.5111 27665945

58. Krizhanovsky V, Yon M, Dickins RA, Hearn S, Simon J, Miething C, et al. Senescence of activated stellate cells limits liver fibrosis. Cell. 2008;134(4):657–67. doi: 10.1016/j.cell.2008.06.049 18724938

59. Mellone M, Hanley CJ, Thirdborough S, Mellows T, Garcia E, Woo J, et al. Induction of fibroblast senescence generates a non-fibrogenic myofibroblast phenotype that differentially impacts on cancer prognosis. Aging (Albany NY). 2016;9(1):114–32.


Článek vyšel v časopise

PLOS One


2019 Číslo 9
Nejčtenější tento týden
Nejčtenější v tomto čísle
Kurzy

Zvyšte si kvalifikaci online z pohodlí domova

Svět praktické medicíny 1/2024 (znalostní test z časopisu)
nový kurz

Koncepce osteologické péče pro gynekology a praktické lékaře
Autoři: MUDr. František Šenk

Sekvenční léčba schizofrenie
Autoři: MUDr. Jana Hořínková

Hypertenze a hypercholesterolémie – synergický efekt léčby
Autoři: prof. MUDr. Hana Rosolová, DrSc.

Význam metforminu pro „udržitelnou“ terapii diabetu
Autoři: prof. MUDr. Milan Kvapil, CSc., MBA

Všechny kurzy
Kurzy Podcasty Doporučená témata Časopisy
Přihlášení
Zapomenuté heslo

Zadejte e-mailovou adresu, se kterou jste vytvářel(a) účet, budou Vám na ni zaslány informace k nastavení nového hesla.

Přihlášení

Nemáte účet?  Registrujte se

#ADS_BOTTOM_SCRIPTS#